Claire Williams
PhD
Senior Researcher
Claire Williams joined HERC in August 2019 as a Senior Researcher focused on cardiovascular disease modelling. She works on lifetime risk projections of cardiovascular events and associated healthcare costs for individual patient profiles based on large randomised control trials (REVEAL, CTT).
Immediately prior to joining HERC, Claire focused on cost-effectiveness modelling and Value of Information analysis to evaluate the use of wound dressings to reduce surgical site infections.
Claire brings with her extensive experience as a medical statistician in both the NHS and academia. She completed her PhD exploring the potential of the continuous-time approach to multi-state modelling in an epidemiological and health economics context within the Health Economics and Health Technology Assessment research group at the University of Glasgow.
She has a particular ongoing interest in the use of state transition modelling and its implementation in R and in comparing them to other methods of clinical- and cost-effectiveness analysis.
Recent publications
-
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study.
Journal article
Mihaylova B. et al, (2024), Lancet Reg Health Eur, 40
-
Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial.
Journal article
Zhou J. et al, (2024), Pharmacoeconomics, 42, 261 - 273
-
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
Journal article
Wu R. et al, (2024), Br J Gen Pract, 74, e189 - e198
-
Impact of New Cardiovascular Events on Quality of Life and Hospital Costs in People With Cardiovascular Disease in the United Kingdom and United States.
Journal article
Lui JNM. et al, (2023), J Am Heart Assoc, 12
-
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.
Journal article
Zhou J. et al, (2023), Pharmacoeconomics, 41, 547 - 559